Pre-Eclampsia - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 50 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Pre-Eclampsia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Pre-Eclampsia - Pipeline Review, H2 2014', provides an overview of the Pre-Eclampsia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pre-Eclampsia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pre-Eclampsia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pre-Eclampsia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pre-Eclampsia Overview 6
Therapeutics Development 7
Pipeline Products for Pre-Eclampsia - Overview 7
Pipeline Products for Pre-Eclampsia - Comparative Analysis 8
Pre-Eclampsia - Therapeutics under Development by Companies 9
Pre-Eclampsia - Therapeutics under Investigation by Universities/Institutes 10
Pre-Eclampsia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Pre-Eclampsia - Products under Development by Companies 14
Pre-Eclampsia - Products under Investigation by Universities/Institutes 15
Pre-Eclampsia - Companies Involved in Therapeutics Development 16
A1M Pharma AB 16
Alnylam Pharmaceuticals, Inc. 17
Glenveigh Medical, LLC 18
Pluristem Therapeutics Inc. 19
rEVO Biologics 20
VG Life Sciences, Inc. 21
Pre-Eclampsia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
ALN-AGT - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Alpha-1-Microglobulin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
antithrombin alfa (recombinant) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
digoxin immune fab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Stem Cell Therapy for Pre-Eclampsia - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
VG-1177 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Pre-Eclampsia - Recent Pipeline Updates 40
Pre-Eclampsia - Dormant Projects 42
Pre-Eclampsia - Product Development Milestones 43
Featured News & Press Releases 43
Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia 43
Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting 44
Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Preeclampsia (PRESERVE-1) 44
Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma's Treatment for Preeclampsia 45
Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Preeclampsia 46
Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Preeclampsia 46
Feb 20, 2014: Pluristem Submits FDA Orphan Drug Application for Preeclampsia 47
Nov 04, 2013: Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables
Number of Products under Development for Pre-Eclampsia, H2 2014 7
Number of Products under Development for Pre-Eclampsia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Pre-Eclampsia - Pipeline by A1M Pharma AB, H2 2014 16
Pre-Eclampsia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 17
Pre-Eclampsia - Pipeline by Glenveigh Medical, LLC, H2 2014 18
Pre-Eclampsia - Pipeline by Pluristem Therapeutics Inc., H2 2014 19
Pre-Eclampsia - Pipeline by rEVO Biologics, H2 2014 20
Pre-Eclampsia - Pipeline by VG Life Sciences, Inc., H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Pre-Eclampsia Therapeutics - Recent Pipeline Updates, H2 2014 40
Pre-Eclampsia - Dormant Projects, H2 2014 42